Accumulation of lipofuscin in the retina is associated with pathogenesis of atrophic age-related macular degeneration and Stargardt disease. Lipofuscin bisretinoids (exemplified by N-retinylidene-N-retinylethanolamine) seem to mediate lipofuscin toxicity. Synthesis of lipofuscin bisretinoids depends on the influx of retinol from serum to the retina. Compounds antagonizing the retinol-dependent interaction of retinol-binding protein 4 (RBP4) with transthyretin in the serum would reduce serum RBP4 and retinol and inhibit bisretinoid formation. We recently showed that A1120 (3), a potent carboxylic acid based RBP4 antagonist, can significantly reduce lipofuscin bisretinoid formation in the retinas of Abca4 −/− mice. As part of the NIH Blueprint Neurotherapeutics Network project we undertook the in vitro exploration to identify novel conformationally flexible and constrained RBP4 antagonists with improved potency and metabolic stability. We also demonstrate that upon acute and chronic dosing in rats, 43, a potent cyclopentyl fused pyrrolidine antagonist, reduced circulating plasma RBP4 protein levels by approximately 60%. Figure 4. (A) Overlay of protein crystal structures 3bsz (orange) and 3fmz (white)
■ INTRODUCTION
Age-related macular degeneration (AMD) is the leading cause of blindness for individuals aged 60 years or older. 1 An estimated 11 million people in the United States suffer with AMD, and this number is expected to increase to 22 million individuals by 2050 because of the projected demographic expansion of the aging population. Current global direct health care costs associated with AMD are estimated at $255 billion. 2 There are two forms of AMD, dry (atrophic) and wet (neovascular), with the more prevalent dry form accounting for nearly 90% of all diagnosed cases. 3 Intravitreal anti-VEGF therapies have emerged as a standard of care to treat wet AMD; however, there is currently no FDA-approved treatment available for the dry form. 3 Thus, safe and effective treatment of dry AMD remains a critical unmet need.
Atrophic (dry) form of AMD represents a slowly progressing neurodegenerative disorder of the eye in which specialized retinal neurons (rod and cone photoreceptors) degenerate in the central part of the retina called macula. 3 Histopathological and clinical data suggest that photoreceptor degeneration in dry AMD is triggered by abnormalities in the retinal pigment epithelium (RPE) that lies beneath photoreceptors and provides critical metabolic support to these light-sensing neuronal cells. 4 Agedependent accumulation of lipofuscin in the RPE is frequently cited as one of the causes that may potentially contribute to the demise of the RPE in the dry AMD retina. 4b,c,5 Moreover, excessive accumulation of lipofuscin in the retina seems to be the sole causative factor in autosomal recessive Stargardt disease, an untreatable form of inherited macular dystrophy caused by genetic mutations in the ABCA4 gene. RPE lipofuscin is different from that of other aging tissues, as it contains various bisretinoid fluorophores 5c,6 such as pyridinium bisretinoid N-retinide-Nretinylidene ethanolamine (A2E). 5c A2E, which is derived from a nonenzymatic condensation between phosphatidylethanolamine and two molecules of all-trans retinal, elicits a myriad of cytotoxic effects such as induction of apoptosis in cultured RPE cells, 5b,7 inhibition of the critical lysosomal transporter, 8 loss of membrane integrity, 9 inhibition of phagocytosis, 5a,10 disruption of mitochondrial function, 10 activation of the complement cascade, 11 and oxidative damage. 12 Given that lipofuscin bisretinoids represent the major cytotoxic component of RPE lipofuscin, it was hypothesized that pharmacological inhibition of bisretinoid formation in the retina may provide a means by which to delay the progression of geographic atrophy in dry AMD and suppress degenerative processes in Stargardt disease. 13 Indeed, there are several classes of pharmacological treatments inhibiting lipofuscin bisretinoid formation in the retina under investigation for the potential treatment of dry AMD and Stargardt's disease. 3, 14 Our work focuses on reducing ocular uptake of serum all-trans retinol (retinol, vitamin A) (1, Figure 1 ) via inhibition of retinol binding protein 4 (RBP4) as a means by which to reduce the concentration of bisretinoid precursors in the retina and inhibit bisretinoid formation. Retinol is an essential nutrient that plays a critical role in a wide variety of biological functions, including fueling the visual cycle. 15 It is transported to vitamin A dependent tissues as a tertiary complex with RBP4 and transthyretin (TTR). 16 RBP4 is a lipocalin serum protein 17 primarily secreted from the liver 18 and to a lesser extent from kidney and adipose tissue. 19 Because of the relatively low molecular weight of RBP4 (21 kDa) , the RBP4-TTR interaction is critical for maintaining serum retinol in circulation as, without complexation with TTR, RBP4-retinol is rapidly cleared from the bloodstream through glomerular filtration. 15 RBP4-TTR complexation is retinol dependent, as apo-RBP4 interacts poorly with TTR. 16 The visual cycle depends on a constant delivery of retinol to the RPE by RBP4. It was suggested that RBP4 ligands antagonizing the retinol-dependent RBP4-TTR interaction in circulation would lead to a dramatic reduction in serum levels of RBP4 via renal elimination of the monomeric protein. As a consequence of this renal RBP4 elimination, serum retinol levels and delivery to the RPE would also be reduced, as would the rate of bisretinoid formation in the retina. 13a This hypothesis has been preclinically and clinically confirmed with fenretinide (2), a synthetic retinoid-based RBP4 antagonist. Fenretinide is known to prevent the binding of all-trans retinol to RBP4 and disrupt the retinol-dependent RBP4-TTR interaction in vitro, 20 as well as lower circulating plasma RBP4 levels in vivo. 13a,21 In addition, fenretinide also significantly reduced accumulation of lipofuscin bisretinoids in the Abca4 −/− mouse model of enhanced retinal lipofuscinogenesis. 13a Supporting the therapeutic role of RBP4 in dry AMD, in extended clinical studies, fenretinide was recently confirmed to reduce serum RBP4 in AMD patients. 22 Post hoc analysis of the fenretinide clinical trial data suggests efficacy in reducing the rate of the geographic atrophy growth that was achieved in a subgroup of patients wherein an approximately 70% (or greater) reduction in serum RBP4 levels was realized. 22 Prior to their application to the treatment of dry AMD and Stargardt disease, RBP4 antagonists were previously being considered for the treatment of diabetes. 19b,c,23 A1120 (3), a lead molecule for this indication, was previously reported by a group at Amgen as was its protein-bound crystal structure. 24 This relatively low molecular weight compound features several key structural elements; an o-trifluoromethyl arylpiperidine linked via a carbonyl to an unsubstituted anthranilic acid residue. In a study reported elsewhere, 25 we have shown that chronic A1120 administration reduced accumulation of lipofuscin bisretinoids by approximately 50% in the Abca4 −/− mouse model. This activity correlated with a 75% reduction in serum RBP4 and 30− 50% reduction in certain visual cycle retinoids. 25 However, despite these encouraging preclinical data, A1120 suffers from poor human liver microsomal (HLM) stability (∼3% remaining after 30 min incubation), thus posing a significant challenge for further development. Therefore, our aim was to design a novel and potent nonretinoid RBP4 antagonist capable of lowering serum RBP4 levels in vivo with comparable or superior efficacy and improved druglike characteristics that include an improved HLM metabolic profile.
The specific protein movements and molecular interactions that mediate agonist driven RBP4-TTR interaction versus holoenzyme and/or antagonist-bound RBP4-TTR disassociation are of great interest in the design of highly potent and selective RBP4 antagonists. It is for this reason that in our program we measured compound binding affinity to the non-TTR associated RBP4 protein (SPA) as well as determined the RBP4-TTR antagonist potency (HTRF) . From evaluation of the reported A1120-bound protein crystal structure, we speculated that variation in both the linkage and relative orientation of the otrifluoromethylphenyl and arylcarboxylic acid fragments might (1), fenretinide (2) , and A1120 (3) . further enhance RBP4 antagonist potency as well as permit tuning of the desirable ADME characteristics so as to potentially improve HLM stability ( Figure 2 ). Using computer-assisted drug design based around several RBP4 protein crystal structures, we designed, computationally evaluated, and synthesized illustrative examples of conformationally constrained carboxylic acid based non-retinoid antagonists. In addition, within the context of the original A1120 structural scaffold, we further explored the RBP4 antagonist activity of several acylsulfonamide carboxylic acid isosteres and arylcarboxylic acid replacements. Lastly, acknowledging earlier patent disclosures of conformationally flexible RBP4 antagonists, 26 we also included in our test set several aliphatic analogues bearing an ether-linked ortho-substituted aryl headgroup and terminal urea-linked carboxylic acid.
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■ CHEMISTRY
By employment of the route reported by Swanson and coworkers (Scheme 1), 27 the synthesis of A1120 (3) and piperidine core intermediate 7 began with lithium−halogen exchange of 1bromo-2-(trifluoromethyl)benzene (4) followed by 1,2-carbonyl addition of the lithium salt to 1-benzylpiperidin-4-one to give tertiary alcohol 5. Thionyl chloride induced dehydration of 5 to the intermediary tetrahydropyridine 6 followed by reduction of the olefin with concomitant N-benzyl deprotection using ammonium formate and 10% Pd/C to afford 7 upon conversion to the hydrochloride salt. Treatment of 7 with methyl 2isocyanatobenzoate followed by saponification of the methyl ester provided A1120 (3) in good yield. Our initial strategy to generate acylsulfonamide acid isosteres of 3 involved HATUmediated activation of the carboxylic acid to be followed by acylation with various desired sulfonamides. However, we discovered that treatment of 3 with HATU in the absence of nucleophile yielded acyl β-lactam 8, which was isolated via column chromatography. Acyl β-lactam 8 ultimately provided a convenient intermediate for the assembly of our desired acylsulfonamides 9−11, as it readily underwent ring-opening to the desired analogues upon treatment with preformed sulfonamide sodium salts.
Highlighted in Scheme 2 are the synthetic routes used to access analogues bearing aliphatic carboxylic acid residues. Piperidine hydrochloride 7 provided a key intermediate for the synthesis of several analogues designed to replace the acylanthranilic acid of 3 with diverse moieties potentially capable of engaging in similar RBP4 binding interactions. Oxoacids 12− 14 were readily manufactured via acylation of 7 with the corresponding carboxylic acid ester, acid chloride, or anhydride followed by saponification of the pendent ester (if required) to give the desired compound. A racemic mixture of proline-based analogue (±)-15 was generated by reaction of methyl 1-(chlorocarbonyl)pyrrolidine-2-carboxylate with 7 followed by hydrolysis of the ester to the desired acid.
The synthesis of acyclic phenoxyethylamido ether analogues 20, 21, 25, and 27 is depicted in Scheme 3. S N 2 displacement of bromide 17 with an appropriately substituted phenol followed by TBS deprotection gave hydroxyl aryl ethers 18. Dess−Martin oxidation to the aldehyde and subsequent reductive amination with methylamine afforded phenoxyethylamines 19. Treatment of intermediate 19 with methyl 2-isocyanatobenzoate followed by saponification of the methyl ester gave the desired carboxylic acid analogues 20 and 21. The syntheses of analogues 25 and 27 began with Boc protection of 2-chloroethanamine 22 to give carbamate 23, which was converted to aryl ether 24 via S N 2 displacement with 2-(tert-butyl)phenol. Intermediate 24 was converted to analogue 25 via treatment with methyl 2-isocyanatobenzoate followed by hydrolysis of the methyl ester to the desired carboxylic acid. Intermediary carbamate 23 was also used in a similar fashion to generate the 4-fluorophenyl substituted analogue 27.
The synthesis of various conformationally constrained analogues is depicted in Scheme 4. Similar to the synthesis of A1120, the manufacture of these compounds involved treatment of a core secondary amine with methyl 2-isocyanatobenzoate followed by saponification of the resulting ester to give the desired acids. The synthesis of 3.1.0 bicyclic systems 29 and 30 followed a procedure reported by McHardy and co-workers. 28 2, heptane 31 was synthesized following chemistry reported by Carreira. 29 Lastly, the aryloxy azetidine core used in the synthesis of analogue 33 followed a synthetic route outlined by Pettersson and co-workers. 30 The synthesis of azepine 28, azetidine 32, and a racemic mixture of spiroindane (±)-34 began with the commercially available secondary amine cores.
Construction of the bicyclic {3.3.0}-octahydrocyclopenta[c]pyrrolo analogues 43, (±)-45, and 48 was achieved following routes previously reported by Dart, 31 Lauffer, 32 and Guillemont 33 (Scheme 5) . The synthesis began with a LiAlH 4 reduction of commercially available dione 35 followed by N-Boc protection of the resulting secondary amine to give isoindole 36 in good yield. NaIO 4 and RuO 2 ·H 2 O facilitated oxidative cleavage of 36 gave ring-opened diacid 37 in good yield. Subsequent Dieckman condensation with concomitant decarboxylation of 37 in acetic anhydride at 120°C yielded ketone 38 in 55% yield. Deprotonation of 38 with LiHMDS followed by treatment with 1,1,1-trifluoro-N-phenyl-N-((trifluoromethyl)sulfonyl)methanesulfonamide provided desired triflate 39, which underwent smooth conversion to alkene (±)-40 in the presence of (2-(trifluoromethyl)phenyl)boronic acid under standard Suzuki Pd-catalyzed cross-coupling conditions. Reduction of alkene (±)-40 via 50 psi of H 2 in the presence of 10% Pd/ C in CH 3 deprotection of 41 followed by reaction with methyl 2isocyanatobenzoate and subsequent saponification of the methyl ester afforded desired carboxylic acid analogue 43. The core geometry of endo-isomer 43 was confirmed via a 1 H NMR NOESY experiment, which exhibited a positive NOE enhancement between the benzylic and bridging methine hydrogens. Generation of exo-product 48 could only be achieved via reduction of des-Boc olefin (±)-44, which provided a mixture of endo-and exo-isomers 46 (free-base of 42) and 47, with endo-46 being the major isomer by HPLC (∼10:1 endo/exo). Secondary amines 46 and 47 were separable via reversed phase column chromatography. This result was consistent with the observation reported by Dart and co-workers 31 and could be attributed to reduction readily occurring at the more accessible convex face of the olefin (±)-44. The greater degree of selectivity observed for the reduction of N-Boc protected intermediate (±)-40 to yield exclusively endo-isomer 41 could be due to further hindrance of hydrogen delivery to the convex face of the olefin by the bulky Boc group. The core geometry of exo-isomer 48 was also confirmed via a 1 H NMR NOESY experiment, which did not exhibit an NOE enhancement between the benzylic and bridging methine hydrogens.
Related analogues of 43 were accessed via carbamoyl chloride intermediate 49, which was generated via treatment of amine hydrochloride salt 42 with triphosgene in the presence of pyridine (Scheme 6). Intermediate 49 was reacted with various methyl 2-amino-5-substituted benzoates, which were subsequently hydrolyzed to the desired carboxylic acid analogues 50− 53.
Carbamoyl chloride 49 could also be treated with heteroanthranilic esters to provide the pyridyl and pyridazinyl bicyclic {3.3.0}-octahydrocyclopenta [c] pyrrolo analogues 54−57 depicted in Scheme 7. Pyridine analogue 54 required an alternative route, which involved a Pd-catalyzed amidation of the primary urea of 49 with 2-chloronicotinate.
The amino acid derived analogues shown in Scheme 8 were also furnished from key carbamoyl chloride intermediate 49 via treatment with the specified amino acid methyl esters followed by hydrolysis to give the desired carboxylic acids.
■ RESULTS AND DISCUSSION
Computational Docking of Proposed Ligands Using 3fmz X-ray Crystallographic Data. Drawing from the breadth of reported RBP4 X-ray crystallographic data available, we sought to gain better insight into key RBP4 binding interactions and conformational changes for both agonist and antagonist binding states, which would serve to evaluate our nonretinoid antagonist design proposals. With this goal in mind, we analyzed binding differences observed in the reported Protein Data Bank (PDB) high-resolution X-ray crystal structures 1rbp (RBP4 cocrystallized with retinol), 34 3bsz (the RBP4-TTR complex cocrystal-lized with retinol), 35 1fel (RBP4 cocrystallized with fenretinide), 16g and 3fmz (RBP4 cocrystallized with A1120). 24 Retinol binds within an internal cavity of RBP4 whereby the polyene chain is encapsulated within a β-barrel core, the βionone ring projects into a deep interior hydrophobic pocket, and the terminal hydroxyl group protrudes out of the entrance of the binding cavity toward solvent ( Figure 3A ). 34 The RBP4 loops β3−β4 (residues 63−68) and β5−β6 (residues 92−99) surround the opening of the binding cavity and present an interaction surface for TTR engagement. 16g, 35 Retinol binding to RBP4 induces conformational changes within these loops that facilitate complexation with TTR. The RBP4-TTR complex is further stabilized via an H-bond interaction between the hydroxyl group of retinol and Gly83 of TTR subunit B. 35 Fenretinide also binds within the RBP4 cavity in a similar fashion to retinol; however, it induces a conformational change within RBP4 loop β3−β4 that is unfavorable for RBP4-TTR engagement ( Figure 3A ). 16g,36 In addition, the fenretinide 4-hydroxyphenylamide is also believed to further disrupt RBP4-TTR complexation by projecting into the RBP4-TTR interaction interface where it presents steric clashes with TTR subunits. 36, 37 A1120 induces significant conformational changes in both RBP4 loops β3−β4 and β5−β6 that are not conducive for complexation with TTR ( Figure 3B ). 24 The nonretinoid antagonist binds within the β-barrel cavity with the otrifluoromethylphenyl ring projecting into the hydrophobic β- Fenretinide is shown as magenta, and retinol is shown as yellow (from 1rbp) and orange (from 3bsz). (B) Comparison of the loop β3−β4 and β5−β6 conformations for retinol and A1120 binding to RBP4: overlay of protein crystal structures 3bsz (green) and 3fmz (red). Retinol is shown as orange, and A1120 is shown as magenta.
ionone pocket and the anthranilic carboxylic acid fragment positioned at the opening where it engages in several key binding interactions; the A1120 carboxamidocarbonyl oxygen atom accepts an H-bond from the backbone of Leu37, and the carboxylic acid forms a salt bridge with Arg121 and two H-bonds with Tyr90 and Gln98 ( Figure 4A ). 24 In addition, a π−π edge-toface interaction is observed between the anthranilic carboxylic acid phenyl ring of A1120 and the phenyl ring of Phe96. Of these key binding interactions, it appears that the A1120-Gln98 Hbond and the Phe96 π−π edge-to-face interaction are potentially playing critical roles in inducing and stabilizing the conformational changes observed within loop β5−β6 (Figures 4B) .
With these crystallographic data in hand, our medicinal chemistry goals were to design novel, nonretinoid antagonists that would engage in the key aforementioned binding interactions and induce conformational changes in both loops β3−β4 and β5−β6, thereby leading to disruption of RBP4-TTR complexation. Proposed ligands were initially docked within 3fmz using Standard Precision (SP) mode, and the docking poses were subsequently refined using the Extra Precision (XP) mode of Glide (version 5.8, Schrodinger, LLC.). We aligned the Glide XP refined docking poses of all proposals to the cocrystallized conformation of A1120 and performed molecular mechanics (MM) minimization on these ligands in 3fmz using Impact (version 5.8, Schrodinger, LLC.). These minimized poses and corresponding Glide scores generated were reported as the final docking poses and Glide scores (Glide scores and solvation energies for each analogue are provided in the Supporting Information). Although Glide scores provided some guidance for the triaging of compounds yet to be synthesized, these crude estimates were generally limited with regard to consistently predicting relative levels of RBP4 binding affinity. We found that these scores were useful in prospectively estimating whether a compound would show affinity at RBP4 with potency (IC 50 ) less than 1 μM in the SPA assay. However, detailed SAR analysis showed that, as expected, the scores exhibited a poor correlation with the actual RBP4 SPA assay IC 50 results observed. In addition, Glide would occasionally provide inconsistent binding modes for some closely structurally related analogues of A1120 (e.g., altered H-bond interactions with either Leu37 or Tyr90). Therefore, focus shifted away from Glide scores and more to the geometric docking of proposed ligands when using the model to triage novel analogue designs prior to synthesis. In this work, our retrospective computational analysis of the RBP4 SPA assay SAR observed for our novel analogues placed emphasis on correlations between the orientation and positioning of our ligands within the RBP4 binding cavity relative to A1120 (geometric docking poses generated) rather than on numeric agreement with the obtained Glide scores.
In Vitro Binding of Compounds to RBP4. Analogue binding affinities for RBP4 were measured using our previously described scintillation proximity assay (SPA). 25 Nonlinear regression analysis conducted following saturation binding of retinol to RBP4 revealed a K d of 62.5 nM in our assay conditions which is in line with the previously reported 70−190 nM range of values. 16d,38 For compound characterization we measured the competitive displacement of radiolabeled retinol added to the reaction mix at 10 nM which roughly corresponds to the generally recommended 1 / 10 of the K d concentration of radioligand. The IC 50 values were calculated from the 12-point compound titrations using a four-parameter logistic equation. Compounds with appreciable RBP4 binding potency (generally, with IC 50 < 150 nM) were further assessed for the ability to antagonize the retinol-dependent RBP4-TTR interaction using the HTRF assay.
Assessment of Antagonistic Activity in the HTRF RBP4-TTR Interaction Assay. The ability of an analogue to disrupt the retinol-induced interaction of RBP4 with TTR was examined using the previously described HTRF assay 25 that probes retinoldependent RBP4-TTR interaction. As indicated in the Experimental Section, we used bacterially expressed maltose binding protein (MBP) tagged RBP4 and commercially available TTR labeled directly with Eu 3+ cryptate along with a d2conjugated anti-MBP monoclonal antibody in order to implement this assay. Retinol added to the reaction mix at 1 μM concentration stimulates RBP4-TTR interaction which brings europium in proximity to the d2 dye with the following fluorescence energy transfer (FRET) to d2. The FRET signal, measured as a 668 nm emission, was normalized using the 620 nm europium emission to compensate for the pipetting and dispensing errors. Following a 12-point dose titration (20 μM to 0.1 nM) the IC 50 values were calculated using a standard fourparameter logistic nonlinear regression model equation. In order to monitor a correlation between the binding affinity of compounds for RBP4 and their potency as antagonists of the retinol-dependent RBP4-TTR interaction, we tracked a ratio of IC 50 values in the HTRF and SPA assays. Despite the difference in binding potency, for the majority of analogues, this ratio tended to be within the 5−20 range.
Structure−Activity Relationships. Table 1 summarizes efforts to replace the carboxylic acid moiety of A1120 with an acylsulfonamide appendage. The docking of analogues 9−11 within our model indicated favorable geometric alignment within the RBP4 binding cavity and engagement in critical H-bond interactions, with the acylsulfonamide appendages projecting out of the binding cavity toward solvent ( Figure 5 ). However, these analogues exhibited a substantial reduction in potency (20-fold or greater) relative to A1120 in both the SPA and HTRF assays. This loss may be partially attributed to significant binding Table 1 . RBP4 SPA Binding Affinity and HTRF Data for Acylsulfonamide and Aliphatic Carboxylic Acid Analogues a IC 50 values for the SPA assay obtained in the presence of a fixed, 10 nM concentration of 3 H-retinol. b IC 50 values for the HTRF assay obtained in the presence of 1 μM concentration of retinol. c Data represent the mean of at least two independent experiments run in duplicate. ND = not determined. penalties incurred by solvent exposure of the hydrophobic acylsulfonamide residues. Interestingly, the HTRF IC 50 values improved slightly with increasing size of the acylsulfonamide appendage, which may suggest that the larger moieties could be projecting into the RBP4-TTR interaction interface in a similar fashion as fenretinide, thereby potentially hindering complexation between the two proteins.
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To further probe the RBP4-arylcarboxylic acid binding region, we explored the potency effects of replacing the anthranilic acid fragment with aliphatic carboxylic acids. To that end, the acylic oxoacids 12−14 and racemic proline analogue (±)-15 were prepared; however, these compounds also exhibited significantly reduced potency. It is possible that less than optimal positioning of the carboxylic acid within the binding cavity, perhaps in combination with diminished interactions with Phe96, contributed to the weak potency values observed for these analogues. The precipitous drop in RBP4 potency observed for this small sample set of analogues, in addition to the potency results obtained for the aforementioned acysulfonamides, prompted us to explore other changes to the scaffold while keeping the anthranilic carboxylic acid appendage intact.
Acyclic N-Methyl-N-(2-phenoxyethyl)amido Analogues. Acknowledging the fact that the poor HLM stability observed for A1120 could be due in part to the piperidine ring presenting potential metabolic soft spots for CYP-mediated oxidation, we explored replacing it with alternative scaffolds in an attempt to probe structural changes that could provide suitable RBP4 antagonist activity with an improved metabolic profile. Drawing from the patent literature, 28 a series of analogues were initially prepared whereby the piperidine ring was replaced with an acyclic N-methyl-N-(2-phenoxyethyl)amido linker in order to impart greater conformational flexibility ( Table 2 ). The complementary o-trifluoromethylphenyl substituted analogue 20 was found to be significantly less potent than A1120 (∼100fold), presumably because of an entropic penalty incurred by the two additional rotatable bonds of the acyclic linkage. However, the o-tert-butylphenyl analogue 25 exhibited dramatically improved potency in the SPA and HRTF assays relative to 20 (SPA IC 50 = 64.8 nM and HTRF IC 50 = 0.554 μM). This observation may be attributed to partial compensation of the entropic penalty incurred via increased van der Waals contacts between the bulkier and more lipophilic tert-butyl group and the hydrophobic surface of the β-ionone pocket within the RBP4 Figure 5 . (A) Overlay of Glide docked poses of analogues 9 (green), 10 (yellow), 11 (orange), and A1120 (magenta) within the RBP4 binding cavity using 3fmz. Analogues 9−11 are shown extending through the cavity in similar fashion to A1120, with the acylsulfonamide and carboxamido moieties engaging in H-bond interactions with Arg121, Gln98, Tyr90, and Leu37 (both not shown), respectively. Contacting residues are labeled and illustrated in stick format. (B) Ligand interaction diagram of analogue 11. (C) Legend for the ligand interaction diagram in the binding pose using MOE. binding cavity. Our docking model showed a good overlay between 25 and A1120, with its carboxylic acid engaged in the key hydrogen bond interactions with Tyr90, Gln98, Arg121, and Leu37 ( Figure 6 ). Despite the encouraging RBP4 potency observed for antagonist 25, poor liver microsomal stability across multiple species was identified as a major liability. The observed poor microsomal stability was presumed to be due to extensive CYP-mediated oxidation of the metabolically labile tert-butyl group and/or the acyclic linkage. Thus, this series was deprioritized, and the team focused its efforts on analogues with more conformationally restricted core scaffolds that might be less susceptible to CYP-mediated oxidation and not require the presence of the metabolically labile o-tert-butylphenyl group to achieve favorable RBP4 binding affinity. Bicyclic {3.3.0}-Octahydrocyclopenta [c] pyrrolo Analogues. Additional analogues that contained novel conformationally restricted cores that linked together the o-trifluoromethylphenyl and arylcarboxylic acid fragments were investigated (Table 3 ). In addition to the aforementioned goal of developing a ligand that was less susceptible to CYP-mediated oxidative metabolism, conformationally restricted cores of varying geometry were also explored so as to probe putative bioactive binding conformations that could potentially lead to analogues with enhanced RBP4 binding affinity. Within the set of compounds tested, the bicyclic {3.3.0}-octahydrocyclopenta[c]pyrrolo analogues 43 and (±)-45 emerged as potent RBP4 antagonists (SPA IC 50 of 72.7 and 148.5 nM, respectively; HTRF IC 50 of 0.294 and 0.481 μM, respectively).
Docking analysis of the active endo-isomer 43 shows favorable alignment within the RBP4 binding cavity (Figure 7) . The bicyclic {3.3.0}-octahydrocyclopenta [c] pyrrolo core is shown extending through the β-barrel with the o-trifluoromethylphenyl ring extending slightly farther into the hydrophobic β-ionone cavity than A1120, and the anthranilic carboxylic appendage is engaged in key H-bond interactions. Interestingly, exo-isomer 48 also exhibited a favorable geometric pose within the model; however the compound was found to be devoid of RBP4 activity (SPA IC 50 > 3 μM). In an attempt to reconcile the discrepancies between the docking experiments and the SPA binding affinities observed for these two geometric isomers, free energy differences associated with minimized bound (docked pose) and unbound ligand conformations were calculated using MacroModel (version 9.9, Schrodinger, LLC.) for both compounds. Indeed, it was determined that the exo-isomer 48 adopts a more strained bound geometry relative to endo-isomer 43 (∼2 kcal/mol greater energy, data not shown) in order to optimize binding interactions with RBP4. While these calculations ignore many other possible effects, they offer a possible explanation for the higher RBP4 binding affinity observed for endo-isomer 43.
In vitro pharmacological evaluation of 43 revealed a desirable profile that included no significant off-target activity at the hERG channel or within a standard screening panel of 55 GPCRs, enzymes, ion channels, and transporters. In addition, 43 exhibited good solubility and metabolic stability, including significantly improved HLM stability ( Table 4 ). The compound did, however, present submicromolar inhibitory activity for CYP2C9 (IC 50 = 340 nM). Thus, a limited set of follow-up analogues was generated in an attempt to diminish CYP2C9 activity and further improve RBP4 potency. We initially explored the SAR impact of an electron withdrawing or donating group substituted para to the urea on the arylcarboxylic acid phenyl ring (50−53). Fluorinated analogue 50 presented SPA potency levels comparable to 43 (SPA IC 50 = 88.8 nM and HTRF IC 50 = 0.285 μM) with moderate HLM stability; however, CYP2C9 activity did not improve (IC 50 = 333 nM). Similarly, chlorinated analogue 52 also exhibited undesirable potency at CYP2C9 (IC 50 = 548 nM) with a concomitant 4-fold diminishment in RBP4 SPA potency relative to 43 (SPA IC 50 = 328.8 nM and HTRF IC 50 = 0.340 μM). Substitution with either methoxy (51) or methylsulfonyl (53) did lead to diminished CYP2C9 activity (IC 50 of 13 and 8.7 μM, respectively); however, the compounds were also significantly less potent for RBP4. Interestingly, replacing the arylcarboxylic acid phenyl ring of 43 with either a pyridine or pyridazine moiety had a dramatic impact on RBP4 binding affinity for the series. It was initially found that the position of the pyridine nitrogen was critical for RBP4 activity, as the 2-aminopyridyl analogue 54 was essentially devoid of activity while the 4-aminopyridyl analogue 55 exhibited RBP4 potency comparable to A1120 (SPA IC 50 = 18.7 nM and HTRF IC 50 = 0.179 μM). Unfortunately, pyridine 55 was found to be a potent CYP3A4 inhibitor (IC 50 < 46 nM); therefore, we sought to mitigate this liability by introducing a methyl group ortho to the pyridyl nitrogen (56). Indeed, analogue 56 exhibited diminished affinity for CYP3A4 (IC 50 = 1.1 μM). In addition, 56 also exhibited improved activity at CYP2C9 (IC 50 = 1 μM) relative to 43, exhibited comparable potency to A1120 in the SPA assay (SPA IC 50 = 23.9 nM), and was within a 2-fold potency range of A1120 in the HTRF assay (HTRF IC 50 = 0.235 μM). Lastly, we found that replacing the methylpyridine of 43 with a pyridazine ring (57) further improved activity at CYP3A4 (IC 50 = 12 μM) and CYP2C9 (IC 50 = 17 μM), provided an overall favorable Figure 6 . Overlay of minimized bound conformations of RBP4 antagonist 25 (green) and A1120 (magenta) within 3fmz. Analogue 25 is shown extending through the cavity in similar fashion to A1120, with its carboxylic acid engaging in H-bond interactions with Arg121, Gln98, and Tyr90 (not shown) and with carboxamide carbonyl interacting with Leu37 (not shown). Contacting residues are labeled and illustrated in stick format. ADME profile (including excellent HLM stability), and yielded an RBP4 antagonist of comparable potency to A1120 in both the SPA and HTRF assays (SPA IC 50 = 24.0 nM and HTRF IC 50 = 0.121 μM).
The superior RBP4 binding affinity of heteroaromatic analogues 55−57 relative to 43 and 50−53 prompted us to explore our computational model and examine if enhanced π−π edge-to-face interactions with Phe96 could be playing a role in the observed potency trends. We conducted ab initio molecular orbital calculations using a simplified model derived from the docked poses of 43, 50, 56, and 57 to identify changes in the electronic distribution of the aromatic and heteroaromatic rings bearing the carboxylic acid and to generate Phe96 interaction scores for each analogue. As expected, the more polarizable heteroaromatic analogues 56 and 57 presented enhanced Phe96 interaction scores relative to 43 and 50 ( Table 5 ). The enhanced polarization of the ring system is indicated by the ab initio derived partial charges at the point of substitution. The increased negative charge of the π-system of the ligand is expected to interact favorably with the C−H atoms of F96 in the predicted edge-to-face geometry. Increased negative charge and the F96 interaction score roughly parallel the increase in activity. These results could indicate that the π−π edge-to-face interactions between the heteroaromatic systems of 55−57 and Phe96 are stronger relative to the nonheteroaromatic analogues, 39 potentially leading to the enhanced binding affinities and HTRF antagonist activity observed for these analogues.
To further probe the RBP4 arylcarboxylic acid binding region of 43, we explored a limited set of amino acid based analogues ( Table 6 ). The glycinergic analogue 58 exhibited weak potency in both the SPA and HTRF assays compared to 43. Interestingly, an enantiopreference for the (S)-isomers was observed for chiral analogues 59−62. The eudismic ratio for (S)-59 and its congener (R)-60 was ∼1.7 for the HTRF assay, and the eudismic ratios for (S)-61 and (R)-62 was ∼10 for both the SPA and HTRF assays, respectively. Notably, (S)-61 exhibited the best potency of this series. Our model suggests that the enantiopreference and superior potency of (S)-61 may be partially attributed to optimal positioning of its carboxylic acid to allow for better engagement with Arg121, Tyr90, and Gln98 relative to (R)-62, as (R)-62 must adopt a higher energy conformation in order for its carboxylic acid to engage in H-bonding interactions with these residues. In addition, the positioning of the phenyl ring of (S)-61 brings it within closer proximity to Phe96 than (R)-62. This closer proximity to Phe96 could present a stronger π−π edge-toface interaction (as evidenced by the F96 interaction scores), which could further contribute to the enantiopreference observed between (S)-61 and (R)-62. In both compounds, the calculated charges of the closest approaching carbon atoms are 0.10 for (S)-61 and 0.16 for (R)-62. The more positive charges suggest that the edge-to-face interaction is weaker for both compounds than those in Table 5 but that (S)-61 would more favorably interact than (R)-62.
The favorable in vitro RBP4 potency and ADME profile of 43 prompted us to evaluate the compound in rodent acute and chronic dosing pharmacokinetic (PK) and pharmacodynamic (PD) experiments. Following iv administration of 0.5 mg/kg, 43 was slowly eliminated from plasma with a mean apparent terminal phase elimination half-life of 10.3 h. The estimated total body clearance of 43 was low (mean, 35.3 mL h −1 kg −1 ), and the estimated apparent volume of distribution at steady state was small (mean, 523 mL/kg). These data are suggestive of a slow rate of metabolism/elimination and limited extravascular distribution of the compound. No unchanged 43 was quantifiable in urine samples collected between 0 and 48 h after iv administration of the compound.
Following po administration of 5 mg/kg as a single dose on day 0, a mean peak plasma concentration of 43 of 3950 ng/mL and an AUC INF of 43 898 h·ng/mL were observed ( Table 7 ). The oral bioavailability of 43 after dosing on day 0, as estimated from AUC INF values, was 31%. For rats given a single daily po dose for 6 consecutive days, plasma concentrations of 43 prior to dosing on day 6 (i.e., approximately 24 h after administration of the previous dose) ranged from 243 to 453 ng/mL. Following dose administration on day 6, mean peak plasma concentrations of 43 and AUC INF were slightly higher than observed on day 0. The estimated oral bioavailability of 43 on day 6 was 44%.
In order to demonstrate the in vivo target engagement, establish the proof of in vivo activity, and document PK−PD correlations, we studied the effect of 43 dosing in rats on the level of plasma RBP4. Aliquots of plasma samples collected during the acute and chronic dosing PK experiments were used to analyze plasma RBP4 concentrations as we previously described. 25 After a single 5 mg/kg oral dose of 43, a 30−50% decrease in plasma RBP4 was observed (data not shown), while the 7-day oral administration in rats at 5 mg/kg induced an approximately 60% reduction in plasma RBP4 ( Figure 8A ). Comparison of the dynamics of RBP4 lowering in response to 43 treatment ( Figure  8A ) with plasma compound levels ( Figure 8B) shows a good correlation between the reduction in plasma RBP4 and increase in compound concentration. Given the absolute correlation between RBP4 lowering and bisretinoid reduction in the Abca4 −/− mouse model of enhanced retinal lipofuscinogenesis, which we and others previously established for the antagonists of the RBP4-TTR interaction from different structural classes, 13a,25 it seems reasonable to expect that 43 and similar analogues with good RBP4 lowering potency will show the desired preclinical efficacy in the Abca4 −/− mice. ■ CONCLUSIONS A1120 is a potent, nonretinoid RBP4 antagonist (SPA IC 50 = 14.8 nM and HTRF IC 50 = 155.5 nM) that induces significant lowering of serum RBP4 levels in vivo and has exhibited efficacy in a preclinical rodent model of excessive lipofuscin accumulation in the RPE. Despite its attractive profile, further development of A1120 as a potential therapeutic to treat dry AMD is hampered by the compound's poor HLM stability (∼3% remaining after a 30 min incubation time). Therefore, using A1120 as a template, we sought to explore various structural changes that could provide an novel RBP4 antagonist of comparable potency but with improved HLM stability. We investigated several modifications, beginning with the acylsulfonamide carboxylic acid isosteres 9−11 and the aliphatic carboxylic acids 12−(±)-15. This set of analogues did not yield potent antagonists, and our program quickly shifted focus on modifying the core while keeping the anthranilic acid appendage intact.
Several structural modifications were made to the core, whereby the piperidine ring was replaced with an acyclic and various conformationally constrained motifs. Among the novel [c] pyrrolo RBP4 antagonist 43 exhibits potent in vitro RBP4 SPA (IC 50 = 73 nM) and HTRF (IC 50 = 294 nM) assay activity that is comparable to A1120. The compound also possesses a favorable ADME profile with excellent HLM stability (100% remaining after a 30 min incubation time) and no limiting off-target pharmacology with the exception of CYP2C9 inhibitory activity (IC 50 = 340 nM). Furthermore, compound 43 possesses good PK and PD properties, leading to a robust and sustained lowering (>85%) of serum RBP4 levels in both acute and chronic rodent oral dosing studies. [c] pyrrolo series led to the discovery of pyridazine 57, which exhibited potent in vitro RBP4 antagonist activity (SPA IC 50 = 24 nM and HTRF IC 50 = 121 nM), favorable ADME profiles, and improved activity at CYP2C9 (IC 50 = 17 μM). Encouraged by these results, we have continued to focus our efforts within the bicyclic {3.3.0}-octahydrocyclopenta[c]pyrrolo series. Additional refinements have led to RBP4 antagonists possessing exquisite in vitro potency, robust in vivo serum RBP4 lowering capability, and efficacy in the Abca4 −/− mouse model. These promising data will be reported in due course.
■ EXPERIMENTAL SECTION
General Chemistry. All reactions were performed under a dry atmosphere of nitrogen unless otherwise specified. Indicated reaction temperatures refer to the reaction bath, while room temperature (rt) is noted as 25°C. Commercial grade reagents and anhydrous solvents were used as received from vendors, and no attempts were made to purify or dry these components further. 3-(2-(Trifluoromethyl)phenyl)azetidine hydrochloride was purchased from Small Molecules [CAS number 1203684-79-0]. 2,3,4,5-Tetrahydro-1H-benzo [d] azepine was purchased from Acros . tert-Butyl 2,6diazaspiro [3.3] -85-3] . Removal of solvents under reduced pressure was accomplished with a Buchi rotary evaporator at approximately 28 mmHg pressure using a Teflon-linked KNF vacuum pump. Thin layer chromatography was performed using 1 in. × 3 in. AnalTech no. 02521 silica gel plates with fluorescent indicator. Visualization of TLC plates was made by observation with short wave UV light (254 nm lamp), 10% phosphomolybdic acid in ethanol or in iodine vapors. Preparative thin layer chromatography was performed using Analtech, 20 cm × 20 cm, 1000 μm preparative TLC plates. Flash column chromatography was carried out using a Teledyne Isco CombiFlash Companion unit with RediSep Rf silica gel columns. If needed, products were purified by reverse phase chromatography, using a Teledyne Isco CombiFlash Companion unit with RediSep Gold C18 reverse phase column. Proton NMR spectra were obtained on either a 300 MHz Bruker nuclear magnetic resonance spectrometer or a 500 MHz Bruker nuclear magnetic resonance spectrometer. Chemical shifts (δ) are reported in parts per million (ppm), and coupling constant (J) values are given in Hz, with the following spectral pattern designations: s, singlet; d, doublet; t, triplet; q, quartet; dd, doublet of doublets; m, multiplet; br, broad. Tetramethylsilane was used as an internal reference. Melting points are uncorrected and were obtained using a MEL-TEMP Electrothermal melting point apparatus. Mass spectroscopic analyses were performed using positive mode electron spray ionization (ESI) on (2) Step A. To a solution of 1-bromo-2-(trifluoromethyl)benzene (4, 35.0 g, 156 mmol) in THF (350 mL) cooled to −78°C was slowly added a solution of n-BuLi (70.4 mL, 2.5 M in THF, 176 mmol) over a period of 15 min. The mixture was stirred at −78°C for 40 min, was allowed to warm to 0°C and then cooled back to −78°C. To this was added a solution of 1benzylpiperidin-4-one (22.1 g, 117 mmol) in THF (80 mL) over a period of 10 min. The resulting mixture continued to stir at −78°C for 2 h. The reaction was carefully quenched with aqueous, saturated NH 4 Cl solution (500 mL), and the mixture was extracted with EtOAc (300 mL). The organic extract was washed with H 2 O, brine, dried over Na 2 SO 4 , filtered, and concentrated under reduced pressure. The resulting residue was chromatographed over silica gel (Isco CombiFlash Companion unit, 330 g RediSep column, 0−30% EtOAc in hexanes) to give 1-benzyl-4-(2-(trifluoromethyl)phenyl)piperidin-4-ol (5) Step B. A 0°C cooled solution of 1-benzyl-4-(2-(trifluoromethyl)phenyl)piperidin-4-ol (5, 29.2 g, 87.1 mmol) in thionyl chloride (60 mL) stirred for 2 h and was then diluted with CH 2 Cl 2 (250 mL). The mixture was carefully poured into a solution of aqueous, saturated NaHCO 3 solution (200 mL). The biphasic mixture was separated, and the aqueous layer was further extracted with CH 2 Cl 2 (400 mL). The combined organic layers were washed with brine, dried over Na 2 SO 4 , filtered, and concentrated. The resulting residue was chromatographed over silica gel (Isco CombiFlash Companion unit, 330 g RediSep column, 0−30% EtOAc in hexanes) to give 1-benzyl-4-(2-(trifluoromethyl)phenyl)-1,2,3,6-tetrahydropyridine (6) Step C. A mixture of 1-benzyl-4-(2-(trifluoromethyl)phenyl)-1,2,3,6tetrahydropyridine (6, 13.6 g, 42.5 mmol) , 10% Pd/C (3.0 g), and ammonium formate (26.8 g, 425 mmol) in CH 3 OH (800 mL) was heated at reflux for 2 h. The mixture cooled to rt and was filtered over Celite. The filtrate was concentrated and the resulting residue was chromatographed over silica gel (Isco CombiFlash Companion unit, 330 (5.6 g, 24.5 mmol) in CH 3 CN (30 mL) was added a 4 M solution of HCl in 1,4-dioxane (6.1 mL, 24.5 mmol) at rt. The mixture stirred for 2 h and was then concentrated under reduced pressure to give 4-(2-(trifluoromethyl)phenyl)piperidine hydrochloride (7) as a white solid (6.4 g, >99%) : ESI MS m/z 230 [M + H] + .
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Step D. A mixture of 4-(2-(trifluoromethyl)phenyl)piperidine hydrochloride (7, 7.89 g, 29.7 mmol) and methyl 2-isocyanatobenzoate (5.27 g, 29.7 mmol) in CH 2 Cl 2 (50 mL) was stirred for 2 h and then chromatographed over silica gel (0−25% EtOAc in hexanes) to give methyl 2-(4-(2-(trifluoromethyl)phenyl)piperidine-1-carboxamido)benzoate as a white solid (8.27 g, 77%) . To a solution of 2-(4-(2-(trifluoromethyl)phenyl)piperidine-1-carboxamido)benzoate (8.0 g, 19.6 mmol) in CH 3 OH (50 mL) and THF (50 mL) was added NaOH (2 N, 20 mL) . The mixture was stirred at rt for 2 h, was diluted with H 2 O (100 mL), and then was acidified to pH 6 with 2 N HCl. The mixture was extracted with CH 2 Cl 2 (3 × 150 mL), and the organic extracts were dried over Na 2 SO 4 , filtered, and concentrated. The residue was chromatographed over silica gel (0−5% CH 3 OH in CH 2 Cl 2 ) to give 2-(4-(2-(trifluoromethyl)phenyl)piperidine-1-carboxamido)benzoic acid (A1120) (3) as a white solid (7.3 g, 95%) . Mp 156−158°C; 1 Step E. To a solution of 2-(4-(2-(trifluoromethyl)phenyl)piperidine-1-carboxamido)benzoic acid (3, 0.711 g, 1.81 mmol) and i-Pr 2 NEt (1.41 mL, 8.15 mmol) in DMF (12.7 mL) was added HATU (1.03 g, 2.72 mmol). The mixture stirred at rt for 1.5 h and was then diluted with aqueous saturated NH 4 Cl (40 mL). The aqueous mixture was extracted with CH 2 Cl 2 (4 × 30 mL), and the combined organic extracts were concentrated under reduced pressure. The resulting residue was Step F. To a 0°C solution of methanesulfonamide (0.057 g, 0.60 mmol) in THF (1.0 mL) was added NaH (60% in mineral oil, 0.024 g, 0.60 mmol), and the resulting solution was stirred at 0°C for 5 min and for an additional 15 min at rt. A solution of 8 (0.150 g, 0.40 mmol) in THF (2.0 mL) was added, and the resulting solution was stirred at rt for 72 h. The reaction was quenched with H 2 O and acidified to pH 4 with 2 N HCl. The resulting precipitate was collected by filtration and washed with H 2 O (40 mL) and hexanes (40 mL). The obtained solids were chromatographed over silica gel (Isco CombiFlash Companion unit, 40 g RediSep column, 0−5% CH 3 OH in CH 2 Cl 2 with 0.05% HOAc) to provide N- (2-((methylsulfonyl) 1-(4-(2-(Trifluoromethyl)phenyl)piperidine-1-carbonyl)pyrrolidine-2-carboxylic Acid (±)- (15) .
Step A. To a solution of 4-(2-(trifluoromethyl)phenyl)piperidine hydrochloride (7, 0.080 g, 0.30 mmol) in CH 2 Cl 2 was added Et 3 N (0.125 mL, 0.90 mmol), followed by methyl 1-(chlorocarbonyl)pyrrolidine-2-carboxylate (0.058 g, 0.30 mmol). The mixture stirred at rt for 6 h, was concentrated, and the resulting residue was chromatographed over silica gel (0−5% CH 3 OH in CH 2 Cl 2 ) to give methyl 1-(4-(2-(trifluoromethyl)phenyl)piperidine-1-carbonyl)pyrrolidine-2-carboxylate as a colorless thick oil (0.098 g, 84%): 1 Step B. To a solution of methyl 1-(4-(2-(trifluoromethyl)phenyl)piperidine-1-carbonyl)pyrrolidine-2-carboxylate (0.098 g, 0.25 mmol) in CH 3 OH (2 mL) and THF (2 mL) was added aqueous 2 N NaOH (2 mL). The mixture stirred at rt for 4 h and was then diluted with H 2 O and acidified to pH 5with 2 N HCl. The mixture was extracted with EtOAc (3 × 30 mL), and the organic extracts were dried over Na 2 SO 4 , filtered, and concentrated under reduced pressure. The residue was chromatographed over silica gel (0−10% CH 3 OH in CH 2 Cl 2 ) to give 1-(4-(2-(trifluoromethyl)phenyl)piperidine-1-carbonyl)pyrrolidine-2-carboxylic acid (±)- (15) (20) .
Step A. A mixture of (2-bromoethoxy)-tertbutyldimethylsilane (4.6 mL, 23.1 mmol), 2-trifluoromethylphenol (2.50 g, 15.4 mmol), KI (0.046 g, 0.27 mmol), and Cs 2 CO 3 (10.0 g, 30.8 mmol) in DMF (69 mL) was heated at 50°C for 18 h. The mixture was allowed to cool to rt and was diluted with H 2 O (300 mL) and extracted with EtOAc (4 × 75 mL). The combined organic extracts were washed with a brine (8 × 50 mL) and concentrated under reduced pressure to give tert-butyldimethyl (2-(2-(trifluoromethyl) Step B. To a solution of tert-butyldimethyl(2-(2-(trifluoromethyl)phenoxy)ethoxy)silane (4.20 g, 13.1 mmol) in 1,4-dioxane (14 mL) was added HCl (4 M in 1,4-dioxane, 14 mL). The mixture was stirred for 3 h, then concentrated under reduced pressure. The obtained oil was diluted with EtOAc (40 mL), washed with a saturated brine solution (30 mL), a 5% LiCl solution (2 × 30 mL), and concentrated under reduced pressure. The resulting residue was chromatographed over silica gel (Isco CombiFlash Rf unit, 80 g RediSep column, 0−50% EtOAc in hexanes) to give 2-(2-(trifluoromethyl)phenoxy)ethanol (18a) as an impure white solid (1.88 g).
Step C. To a 0°C cooled solution of 2-(2-(trifluoromethyl)phenoxy)ethanol (18a, 0.800 g, 3.88 mmol) in CH 2 Cl 2 (25 mL) was added Dess− Martin periodinane (2.50 g, 4.85 mmol) . The mixture was stirred at rt for 18 h, then diluted with CH 2 Cl 2 (30 mL), washed with H 2 O (4 × 30 mL), and concentrated under reduced pressure. The resulting residue was chromatographed over silica gel (Isco CombiFlash Rf unit, 40 g RediSep column, 0−50% EtOAc in hexanes) to give 2-(2-(trifluoromethyl)phenoxy)acetaldehyde a white solid (0.377 g), which was used as is in the next step.
Step D. A solution of 2-(2-(trifluoromethyl)phenoxy)acetaldehyde (0.337 g, 1.65 mmol) in methylamine (2 N in CH 3 OH, 8.3 mL, 16.5 mmol) was stirred at rt for 18 h. The mixture was concentrated to under reduced pressure. The obtained residue was dissolved in EtOH (8.3 mL) and NaBH 4 (0.062 g, 1.65 mmol). The mixture stirred at rt for 2 h and was concentrated under reduced pressure. The resulting residue was diluted in 2 N NaOH (40 mL) and extracted with EtOAc (3 × 30 mL). The organic extracts were combined and concentrated under reduced pressure. The obtained residue was chromatographed over silica gel (Isco CombiFlash Rf unit, 12 g RediSep column, 0−10% CH 3 OH in CH 2 Cl 2 with 0.1% NH 4 OH) to give N-methyl-2-(2-(trifluoromethyl)phenoxy)ethanamine (19a) as a clear oil (0.070 g, 2% for three steps): 1 H NMR (300 MHz, CDCl 3 ) δ 7.59 −7.52 (m, 1H), 7.51−7.42 (m, 1H), 7.05−6.93 (m, 2H) Step E. To a solution of N-methyl-2-(2-(trifluoromethyl)phenoxy)ethanamine (19a, 0.058 g, 0.26 mmol) and Et 3 N (0.027 g, 0.26 mmol) in CH 2 Cl 2 (0.9 mL) was added methyl 2-isocyanatobenzoate (0.047 g, 0.26 mmol). The mixture stirred at rt for 2 h and was then diluted with H 2 O (30 mL) and extracted with CH 2 Cl 2 (3 × 30 mL) . The combined organic extracts were concentrated under reduced pressure. The resulting residue was chromatographed over silica gel (Isco CombiFlash Rf unit, 12 g RediSep column, 0−50% EtOAc in hexanes) to give methyl 2- (3-methyl-3-(2-(2-(trifluoromethyl) phenoxy)ethyl)ureido)benzoate as a white solid (84 mg, 79%): 1 H NMR (300 MHz, ) δ 10.41 (s, 1H), 8.43 (dd, J = 8.7, 0.9 Hz, 1H), 7.94 (dd, J = 7.8, 1.5 Hz, 1H), 3H), 7.30 (d, J = 8.7 Hz, 1H), 2H) Step F. To a solution of methyl 2-(3-methyl-3-(2-(2-(trifluoromethyl)phenoxy)ethyl)ureido)benzoate (0.084 g, 0.21 mmol) in THF (4.2 mL) and CH 3 OH (1.9 mL) was added a solution of LiOH·H 2 O (0.089 g, 2.1 mmol) in H 2 O (0.98 mL). The mixture stirred at rt for 4 h and was then acidified to pH 5 with 2 N HCl and diluted with H 2 O (20 mL). The resulting precipitate was collected by filtration to provide 2- (3-(2-(2-(tert-butyl) phenoxy)ethyl)-3methylureido)benzoic acid (20) as a white solid (0.046 g, 57%): mp 171−173°C; 1 H NMR (500 MHz, ) δ 13.51 (br s, 1H), 10.89 (s, 1H), 8.46 (dd, J = 8.5, 0.5 Hz, 1H), 7.96 (dd, J = 8.0, 1.5 Hz, 1H), 2H), 1H), 7.29 (d, J = 8.5 Hz, 1H), 1H), 1H), 4.27 (t, J = 5.5 Hz, 2H) 2-(3-(2-(2-(tert -Butyl)-4-chlorophenoxy)ethyl)-3methylureido)benzoic Acid (21) . Compound 21 was prepared according to a similar procedure described for the synthesis of 20. Mp 166−169°C; 1 H NMR (500 MHz, ) δ 13.50 (br s, 1H), 10.92 (s, 1H), 8.47 (dd, J = 8.5, 0.5 Hz, 1H), 7.95 (dd, J = 8.0, 1.5 Hz, 1H), 1H), 7.21 (dd, J = 8.5, 2.5 Hz, 1H), 7.31 (d, J = 2.5 Hz, 1H), 2H) (25). Step A. To a −10°C cooled suspension of 2chloroethanamine hydrochloride (35.5 g, 0.306 mol) and NaHCO 3 (102.8 g, 1.22 mol) in THF (450 mL) and H 2 O (450 mL) stirring in a 2 L, three-necked, round-bottomed flask equipped with a thermometer was carefully added a solution of di-tert-butyl dicarbonate (73.4 g, 0.336 mol) in THF (40 mL) dropwise over 30 min. The mixture was allowed to warm to rt and stirred for an additional 24 h. The mixture was diluted with H 2 O (200 mL) and extracted with EtOAc (3 × 150 mL). The combined organic extracts were washed with H 2 O (100 mL), brine (100 mL), dried over Na 2 SO 4 , filtered, and concentrated under reduced pressure to give tert-butyl (2-chloroethyl)carbamate (23) as a clear, colorless oil that was used as is in the next step (60.96 g, quantitative%): 1 H NMR (500 MHz, CDCl 3 ) δ 4.89 (bs, 1H), 3.60 (m, 2H), 3.46 (m, 2H), 1.45 (s, 9H) .
Step B. A 2 L, three-necked, round-bottomed flask equipped with a thermometer, reflux condenser, and mechanical stirrer were charged with tert-butyl (2-chloroethyl)carbamate (23, 65.28 g, 337 mmol), 2-(tert-butyl)phenol (34.0 mL, 222 mmol), KI (0.365 g, 2.20 mmol), Cs 2 CO 3 (183 g, 560 mmol), and DMF (700 mL), and the mixture was heated at 60°C for 16 h. The mixture was allowed to cool to rt and was SO 4 , filtered, and concentrated under reduced pressure. The residue was purified over a plug of silica gel (0−15% EtOAc in hexanes) to give tert-butyl (2-(2-(tert-butyl) phenoxy)ethyl)carbamate (24) as a yellow solid (53.46 g, 82%): 1 H NMR (500 MHz, CDCl 3 ) δ 7. 28 (m, 1H), 7.16 (m, 1H), 6.92 (m, 1H), 6.83 (m, 1H), 4.83 (bs, 1H), 4.07 (m, 2H) , 3.59 (m, 2H), 1.39 (s, 9H) .
Step C. To a 0°C cooled solution of LiAlH 4 in THF (1.0 M, 367 mL, 360 mmol) in THF (350 mL) in a 3 L, three-necked, round-bottomed flask equipped with a thermometer was carefully added a solution of tertbutyl (2-(2-(tert-butyl) phenoxy)ethyl)carbamate (24, 43.06 g, 147 mmol) in THF (100 mL). Upon complete addition, the mixture was allowed to warm to rt followed by heating at 60°C for 16 h. The mixture was allowed to cool back to rt and then further cooled to 0°C. The mixture was carefully quenched by slow addition of H 2 O (15 mL), 15% aqueous NaOH solution (15 mL), followed by additional H 2 O (40 mL). The rate of quenching was done carefully so as to maintain an internal temperature below 25°C. The mixture stirred for 1 h and was filtered through Celite. The aqueous filtrate was extracted with Et 2 O (2 × 150 mL), and the organic extracts were combined, dried over Na 2 SO 4 , filtered, and concentrated under reduced pressure. The residue was purified by flash column chromatography (Isco CombiFlash Rf unit, two 330 g RediSep columns, 0−50% CH 3 OH in CH 2 Cl 2 ) to give 2-(2-(tertbutyl)phenoxy)-N-methylethanamine as an oil (13.4 g). This material was dissolved in Et 2 O (250 mL) and treated with a solution of 2 M HCl in Et 2 O (85 mL) at 0°C. The mixture stirred for 10 min at rt and was concentrated under reduced pressure to give 2-(2-(tert-butyl)phenoxy)-N-methylethanamine hydrochloride as a white solid ( Step D. To a solution of 2-(2-(tert-butyl)phenoxy)-N-methylethanamine hydrochloride (0.066 g, 0.312 mmol) and Et 3 N (0.038 g, 0.381 mmol) in CH 2 Cl 2 (3.0 mL) was added methyl 2-isocyanatobenzoate (0.062 g, 0.352 mmol), and the mixture was stirred at rt for 18 h. The mixture was diluted with H 2 O (30 mL), extracted with CH 2 Cl 2 (3 × 30 mL) , and the combined organic extracts were concentrated under reduced pressure. The resulting residue was chromatographed over silica gel (0−5% CH 3 OH in CH 2 Cl 2 with 0.01% NH 4 OH) to give methyl 2- (3-(2-(2-(tert-butyl) 1.8 Hz, 1H), 1H), 1H), 1H), 1H), 2H) Step E. To a solution of methyl 2- (3-(2-(2-(tert-butyl) Step C. To a solution of tert-butyl (2-(2-(tert-butyl)-4fluorophenoxy)ethyl)(methyl)carbamate (26, 0.490 g, 1.51 mmol) in CH 2 Cl 2 (6.0 mL) was added HCl (2 N solution in Et 2 O, 6.0 mL), and the mixture stirred at rt for 6 h. The mixture was then diluted with Et 2 O (30 mL), and the resulting solids were collected by filtration to give 2-(2-(tert-butyl)-4-fluorophenoxy)-N-methylethanamine hydrochloride as a white solid ( Step D. To a solution of 2-(2-(tert-butyl)-4-fluorophenoxy)-Nmethylethanamine hydrochloride (0.085 g, 0.32 mmol) and Et 3 N (0.066 g, 0.65 mmol) in CH 2 Cl 2 (1.1 mL) was added methyl 2isocyanatobenzoate (0.064 g, 0.326 mmol). The mixture was stirred at rt for 3 h, was then diluted with H 2 O (10 mL), and was extracted with Step E. To a solution of methyl 2-(3-(2-(2-(tert-butyl)-4fluorophenoxy)ethyl)-3-methylureido)benzoate (0.110 g, 0.27 mmol) in THF (5.4 mL) and CH 3 OH (2.8 mL) was added a solution of LiOH· H 2 O (0.114 g, 2.73 mmol) in H 2 O (1.4 mL). The mixture stirred at rt for 18 h, was then acidified to pH 5 with 2 N HCl, and was diluted with H 2 O (30 mL). The resulting solids were collected by filtration and washed with H 2 O to provide 2-(3-(2-(2-(tert-butyl)-4-fluorophenoxy)ethyl)-3methylureido)benzoic acid (27) 2-(2,3,4,5-Tetrahydro-1H-benzo [d] azepine-3-carboxamido)benzoic Acid (28) .
Step A. To a solution of 2,3,4,5-tetrahydro-1Hbenzo [d] Step B. To a solution of methyl 2- (2,3,4,5-tetrahydro-1H-benzo[d] azepine-3-carboxamido)benzoate (0.197 g, 0. 60 mmol) in THF (12.0 mL) and CH 3 OH (5.6 mL) was added a solution of LiOH·H 2 O (0.255 g, 6.07 mmol) in H 2 O (2.8 mL). The mixture stirred at rt for 3 h, was neutralized with 2 N HCl, and was diluted with H 2 O (30 mL). The resulting precipitate was collected by filtration to give 2- (2,3,4,5tetrahydro-1H-benzo[d] azepine-3-carboxamido)benzoic acid (28) (1.43 g, 28.7 mmol) in i-PrOH (100 mL) was heated at reflux for 1 h. The mixture cooled to rt and was concentrated under reduced pressure providing (E)-(2-(trifluoromethyl)benzylidene)hydrazine, which was a yellow oil that crystallized upon standing (5.1 g, 94%) . The material was used as is in the next step.
Step B. To a solution of (E)-(2-(trifluoromethyl)benzylidene)hydrazine (5.0 g, 26.5 mmol) in 1,4-dioxane (200 mL) was added MnO 2 (23.1 g, 256 mmol) portionwise, and the mixture stirred at rt for 3 h. The slurry was filtered through Celite and rinsed with additional 1,4dioxane (50 mL). To the filtrate was added 1-benzyl-1H-pyrrole-2,5dione (4.92 g, 26.5 mmol) , and the mixture was stirred at rt for 48 h. The mixture was concentrated under reduced pressure and the resulting residue was chromatographed over silica gel (Isco CombiFlash Rf unit, 330 g RediSep column, 0−5% EtOAc in hexanes) to give (1R,5S,6s)-3benzyl-6-(2-(trifluoromethyl)phenyl)-3-azabicyclo[3.1.0]hexane-2,4dione (1.52 g, 17%) as a white solid: 1 Step C. To a solution of (1R,5S,6s)-3-benzyl-6-(2-(trifluoromethyl)phenyl)-3-azabicyclo[3.1.0]hexane-2,4-dione (1.24 g, 3.59 mmol) in THF (20 mL) was added NaBH 4 (0.339 g, 8.97 mmol) , and the mixture stirred at rt for 15 min. To this was added BF 3 ·Et 2 O (1.0 M solution in THF, 5.38 mL, 5.38 mmol) dropwise (gas evolution was observed). The mixture was then heated at 50°C for 5 h. The mixture was allowed to cool back to rt and was carefully quenched by dropwise addition of H 2 O (added until gas evolution no longer occurred). To this was added CH 3 OH (60 mL), and the resulting mixture was stirred at reflux for 16 h. The mixture cooled back to rt and was concentrated under reduced pressure. The resulting residue was taken up in H 2 O (50 mL) and extracted with EtOAc (3 × 50 mL). The combined organic extracts were concentrated under reduced pressure, and the resulting residue was chromatographed over silica gel (Isco CombiFlash Rf unit, 12 g RediSep column, 0−25% EtOAc in hexanes) to give (1R,5S,6s)-3-benzyl-6-(2-(trifluoromethyl)phenyl)-3-azabicyclo[3.1.0]hexane as a colorless, viscous oil (0.720 g, 64%): 1 Step D. A mixture of (1R,5S,6s)-3-benzyl-6-(2-(trifluoromethyl)phenyl)-3-azabicyclo[3.1.0]hexane (0.700 g, 2.20 mmol) and 10% Pd/C (0.200 g) in CH 3 OH (50 mL) was subjected to a 50 psi atmosphere of H 2 at rt for 4 h using a Parr shaker apparatus. The mixture was filtered through Celite and the filtrate was concentrated under reduced pressure to give (1R,5S,6s)-6- Step E. To a solution of (1R,5S,6s)-6-(2-(trifluoromethyl)phenyl)-3azabicyclo[3.1.0]hexane (0.100 g, 0.44 mmol) in CH 2 Cl 2 (10 mL) was added methyl 2-isocyanatobenzoate (0.078 g, 0.44 mmol), and the mixture stirred at rt for 2 h. The mixture was diluted with H 2 O (20 mL) and extracted with CH 2 Cl 2 (3 × 30 mL). The combined organic extracts were concentrated under reduced pressure, and the resulting residue was Step F. To a solution of methyl 2-((1R,5S,6s)-6-(2-(trifluoromethyl)phenyl)-3-azabicyclo[3.1.0]hexane-3-carboxamido)benzoate (0.110 g, 0.27 mmol) in THF (2 mL) and CH 3 OH (4 mL) was added 2 N NaOH (2 mL). The mixture was stirred at rt for 3 h and was then acidified to pH 5 with 2 N HCl. The resulting precipitate was collected by filtration to 2-( (1R,5S,6s 2-(6-(2-(Trifluoromethyl)phenyl)-2,6-diazaspiro[3.3]heptane-2-carboxamido)benzoic Acid (31) .
Step A. A mixture of tert-butyl 2,6-diazaspiro [3.3] heptane-2-carboxylate hemioxalate (0.200 g, 1.01 mmol), 1-bromo-(2-trifluoromethyl)benzene (0.14 mL, 1.03 mmol), Pd(dba) 3 (0.014 g, 0.015 mmol), rac-BINAP(0.140 g, 0.225 mmol), and K 2 CO 3 (0.340 g, 3.03 mmol) in toluene (5 mL) was heated at 110°C in a sealed tube for 24 h. The mixture cooled to rt and was diluted with EtOAc (10 mL), filtered through Celite, and the filtrate was concentrated under reduced pressure. The residue was chromatographed over silica gel (Isco CombiFlash Rf unit, 40 g RediSep column, 0−100% EtOAc in hexanes) to provide tert-butyl 6-(2-(trifluoromethyl)phenyl)-2,6-diazaspiro [3.3] heptane-2-carboxylate as a tan solid (0.131 g, 38%): 1 H NMR (500 MHz, CDCl 3 ) δ 7.50−7.48 (m, 1H), 7.37−7.37 (m, 1H), 6.81−6.78 (m, 1H), 6.48 (d, J = 8.5 Hz, 1H), 4.05−4.10 (m, 8H), 1.44 (s, 9H).
Step B. To a solution of tert-butyl 6-(2-(trifluoromethyl)phenyl)-2,6diazaspiro [3.3] heptane-2-carboxylate (0.131 g, 0.38 mmol) in CH 2 Cl 2 (2 mL) was added 2 M HCl in Et 2 O (2 mL), and the mixture stirred at rt for 4 h. The mixture was concentrated under reduced pressure, and the resulting residue was dissolved in CH 2 Cl 2 (4 mL). To this solution were added Et 3 N (0.12 mL, 0.86 mmol) and methyl-2isocyanatobenzoate (80 mg, 0.45 mmol), and the mixture stirred at rt for 24 h. The mixture was washed with saturated aqueous 2 M NaHCO 3 solution (10 mL) and extracted with CH 2 Cl 2 (2 × 10 mL). The combined organic extracts were dried over Na 2 SO 4 , filtered, and concentrated under reduced pressure. The resulting residue was chromatographed over silica gel (Isco CombiFlash Rf unit, 24 g RediSep column, 0−50% EtOAc in hexanes) to provide methyl 2-(6-(2-(trifluoromethyl)phenyl)-2,6-diazaspiro [3.3] heptanes-2-carboxamido)benzoate as an off-white solid (0.080 g, 50%): 1 H NMR (500 MHz, CDCl 3 ) δ 8.52 (d, J = 8.5 Hz, 1H), 1H), 2H), 1H), 2H) Step C. To a mixture of methyl 2-(6-(2-(trifluoromethyl)phenyl)-2,6diazaspiro [3.3] heptanes-2-carboxamido)benzoate (0.080 g, 0.19 mmol) in CH 3 OH (3 mL) and THF (3 mL) was added LiOH·H 2 O (0.080 g, 1.91 mmol) in H 2 O (10 mL). The mixture was stirred at rt for 3 h followed by acidification to pH 6 with 2 N HCl. The mixture was further diluted with H 2 O (10 mL), and the resulting precipitate was collected by filtration. The material was recrystallized from EtOAc and heptanes to provide (31) 2-(6-(2-(trifluoromethyl)phenyl)-2,6-diazaspiro[3.3]heptanes-2-carboxamido)benzoic acid as a white solid (0.049 mg,
